No Data Yet
Legend Biotech announced its CEO, Ying Huang, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference on January 14th, 2026.
The 67th ASH Annual Meeting presented revolutionary clinical data for multiple myeloma, with therapies like CARVYKTI demonstrating the potential for functional cures. These findings are set to alter treatment paradigms and attract significant investment into the oncology sector.
Arcellx and partner Kite (Gilead) announced strong Phase 2 data for their multiple myeloma CAR-T therapy, anito-cel, showing high response rates and durable efficacy. The results, presented at the ASH Annual Meeting, intensify competition in the crowded cell therapy market.